CRNX · Crinetics Pharmaceuticals Inc
Price
Snapshot
50 fields · last close| Market Cap | $9.01B |
| P/E | — |
| Float | 103.0M |
| Beta | 0.45 |
| Volatility | 11.2% |
| Exchange | NASDAQ |
| Sector | Pharmaceuticals |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | — |
| Price | 84.95 |
| Change | +0.00% |
| Prev Close | 84.95 |
| Open | 84.96 |
| Day Low | 84.92 |
| Day High | 85.01 |
| Avg Vol | 3 |
| Avg $ Vol | $256.2M |
| 52W High | 85.01 |
| 52W Low | 30.99 |
| 52W Pos | 99.9% |
| From High | −0.07% |
| From Low | +174.12% |
| Max DD 1Y | −42.21% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.50% |
| SMA 50 | +13.52% |
| SMA 200 | +68.41% |
| RSI (14) | 89.8 |
| Vol 30D | 2.1% |
| Vol 90D | 122.4% |
| 1Y Range | 31–85 |
| Daily bars | 503 |
| Perf Week | +0.20% |
| Perf Month | +1.71% |
| Perf Quarter | +146.09% |
| Perf Half Y | +108.82% |
| Perf Year | +177.16% |
| Perf YTD | +81.79% |
| Prev Day | +0.00% |
| Clavix | — |
| Debt / Eq | 0.00 |
| Curr Ratio | 12.32 |
| Int Cover | — |
| FCF Margin | — |
| Rev Growth | +2336.3% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | — |
Recent news
most recent scored articles · the chip is the article’s score · click to openVertex Pharmaceuticals outlined its growth strategy at a healthcare conference, mentioning its recent acquisition of Crinetics alongside planned kidney disease, pain, and cystic fibrosis pipeline work. The article body is truncated and provides no specific details about the Crinetics deal terms or timing.
Wall Street Zen upgraded Crinetics Pharmaceuticals (CRNX) to a 'hold' rating in a research note issued on Saturday. The article provides no further detail.
Vertex is buying Crinetics for about $10 billion, adding Crinetics' endocrine drugs PALSONIFY and atumelnant to Vertex's pipeline, with Vertex projecting more than $5 billion in peak annual revenue from those drugs.
Vertex Pharmaceuticals has completed its acquisition of Crinetics Pharmaceuticals for approximately $10 billion in equity value (around $8.8 billion after subtracting Crinetics' cash on hand). The deal brings Crinetics' commercial and clinical-stage assets into Vertex and expands Vertex into rare endocrine diseases.
Vertex Pharmaceuticals has finished buying Crinetics Pharmaceuticals (CRNX), which develops treatments for hormone-related diseases. Vertex also announced additions to its executive team to support growth. The article body is short and provides few additional details.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics Inc | B | $8.23B | — | 0.82 | Compare |
| ELAN | Elanco Animal Health Inc | B | $11.77B | — | 1.74 | Compare |
| CORT | Corcept Therapeutics Inc | C | $11.91B | 215.80 | 0.52 | Compare |
| JAZZ | Jazz Pharmaceuticals PLC | A- | $13.65B | 14.51 | 0.38 | Compare |
| MANE | Veradermics Inc | C+ | $4.55B | — | 0.44 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.